Shanghai Yidi Biotechnology Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to an androgen receptor targeting moiety via a linker reported ...

Herbicide development has slowed in recent years, but innovative research methods could soon drive significant progress in ...

Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor targeting moiety through a linker acting as androgen ...

Nine U of A students, the largest group ever, shared their STEM research with elected officials, educators, peers and fellow presenting students from 13 Arkansas institutions.

Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $30.00.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and ...

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

A new editorial was published in Oncoscience’s Volume 12 on January 14, 2025, titled “Pomalidomide improved immune profiles ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...

First, that hybrid ubiquitin chains containing several linkage types play critical roles in regulating innate immune signalling networks; second that the essential roles of TRAF6 in initiating innate ...

Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), ...